Everolimus in Pancreatic Neuroendocrine Carcinomas G3

#1368

Introduction: Neuroendocrine Carcinomas (NEC) G3 are heterogeneous diseases with different behaviors, basing on tumor morphology and Ki67 value. Platinum-based chemotherapy is considered the standard treatment in these pts. However, tumors with well-moderately differentiated morphology (NET G3), with Ki67 < 55% may be considered a separate entity in terms of prognosis and therapeutic options

Aim(s): To investigate everolimus efficacy in pancreatic NET (pNET) G3

Materials and methods: Retrospective analysis of pts with pNET G3 and Ki67 20-55% treated with everolimus

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Panzuto F

Authors: Panzuto F, Rinzivillo M, Spada F, Antonuzzo L, Ibrahim T,

Keywords: Neuroendocrine carcinoma, everolimus,